CheckMate 331 indicated that patients after progress did not benefit from immunotherapy.6 Although the predictive ability of PD-L1 expression has been verified in NSCLC, few predictive biomarkers are available in SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.